Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, announced today the launch of an equity offering by means of a private placement to a group of investors, with the intention to raise an amount of approximately € 10 million, with the possibility to increase the size of the placement. The board of directors has cancelled the preferential subscription right of the existing shareholders in the framework of this transaction, including for the benefit of Biovest Comm. VA., which has indicated its willingness to participate in the transaction. read more
EMBO announced Jiří Friml of the Department of Plant Systems Biology, VIB and Ghent University, Belgium and Central European Institute of Technology, University Brno, Czech Republic as the winner of the 2012 EMBO Gold Medal. read more
Ablynx [Euronext Brussels: ABLX], today announced that its anti-TNFα Nanobody, ozoralizumab (ATN-103), for the treatment of inflammatory diseases, showed excellent safety and efficacy results in the 48-week open-label extension (OLE) study of the worldwide and Japanese Phase II trials in the treatment of patients with Rheumatoid Arthritis (RA) who have an insufficient response to methotrexate alone. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the Belgian tax authorities have granted the Company a positive ruling enabling it to benefit from the “patent income deduction regime” and, therefore, from a reduced tax rate for all patent-related ocriplasmin income. read more